Efficacy News and Research

RSS

Insilico Medicine gets first clinical milestone payment of $10 million for XL309

Insilico Medicine ('Insilico'), a clinical-stage generative artificial intelligence (AI)-driven drug discovery and development company, today announced that it has received the first clinical milestone payment of $10 million for XL309 (previously known as ISM3091) from Exelixis.

12 Dec 2024

Long-CoV-III-21 trial shows positive results for bovhyaluronidase azoximer in post-COVID pulmonary sequelae

Petrovax announced today the positive results from "Long-CoV-III-21," a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of bovhyaluronidase azoximer in adult patients with pulmonary sequelae of COVID-19.

12 Dec 2024

Mediterranean plants show promise for cardiovascular disease treatment

A study initiated from a final degree project at the Universitat Autònoma de Barcelona, with the involvement of researchers from the INc-UAB, the University of Barcelona and Cuban and Chilean institutions, has resulted in an exhaustive bibliographic review of a group of Mediterranean plants, whose active principles are attributed pharmacological actions in the field of cardiovascular diseases most affecting the population.

12 Dec 2024

PATINA trial demonstrates benefit of palbociclib in HR+ HER2+ metastatic breast cancer

Alliance Foundation Trials, LLC (AFT) and Pfizer Inc. today announced results from the phase III PATINA trial demonstrating that the addition of palbociclib (IBRANCE) to current standard-of-care first-line maintenance therapy (following induction chemotherapy) resulted in statistically significant and clinically meaningful improvement in progression-free survival (PFS) by investigator assessment in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC).

12 Dec 2024

Tamoxifen lowers breast cancer recurrence in good-risk DCIS patients

For patients with "good-risk" ductal carcinoma in situ (DCIS) who underwent breast- conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the risk of recurrence in the same breast, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

12 Dec 2024

electronRx to launch purpleDx pulmonary disease smartphone app for remote lung function monitoring

electronRx, a leading digital medicine and biomarker company driving healthcare through pulmonary innovation, today announced that it will launch purpleDx, a cardiopulmonary assessment app built to medical device standards, at CES 2025 from 7-10 Jan in Las Vegas, USA.

12 Dec 2024

PROSPECT-Lung trial aims to improve treatment for patients with resectable non-small cell lung cancer

The highly anticipated PROSPECT-Lung trial has officially opened, marking a significant step forward in the quest to improve treatment strategies for patients with resectable non-small cell lung cancer.

11 Dec 2024

Exosomes: A double-edged sword in hepatocellular carcinoma

The TIME is a dynamic network composed of cancer cells, immune cells, and stromal components. During the early stages of tumorigenesis, the TIME attempts to eliminate abnormal cells through immune surveillance.

11 Dec 2024

Understanding how angiogenesis contributes to drug resistance in breast cancer

Breast cancer, the most common cancer among women, is notorious for its ability to develop resistance to a wide range of treatments, including surgery, chemotherapy, targeted therapies, and immunotherapy.

11 Dec 2024

New class of antivirals shows promise against multiple viruses

The arrival of Paxlovid in December 2021 marked another turning point in the COVID-19 pandemic - an effective antiviral that has since successfully treated millions.

11 Dec 2024

Imlunestrant offers new hope for ER-positive HER2-negative breast cancer

Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free survival in patients with endocrine therapy-pretreated, ER-positive, HER2-negative advanced breast cancer - as monotherapy in patients with ESR1 mutations and as combination therapy with abemaciclib (Verzenio) in all patients, regardless of ESR1 mutation status - according to results from the phase III EMBER-3 clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

11 Dec 2024

Olaparib provides survival benefits for high-risk BRCA-positive breast cancer patients

Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received placebo after a median follow-up of 6.1 years, according to the latest results from the phase III OlympiA clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

11 Dec 2024

TCR sequencing sheds light on tumor immune interactions in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) stands as the dominant form of liver cancer, ranking as the fourth leading cause of cancer-related deaths globally.

11 Dec 2024

Prostate cancer vaccines: Progress, challenges, and future directions

Prostate cancer vaccines, including dendritic and peptide types, offer hope for improved treatments, but face hurdles in clinical effectiveness and validation.

11 Dec 2024

Elevated PGE2 levels drive age-related skin changes and cancer risk

A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 21 on November 18, 2024, entitled, "Prostaglandin E2 regulates senescence and post-senescence neoplastic escape in primary human keratinocytes."

11 Dec 2024

Interim analysis of STOMP study finds no efficacy for tecovirimat in mild to moderate Mpox cases

The antiviral drug tecovirimat did not reduce the time to lesion resolution or have an effect on pain among adults with mild to moderate clade II mpox and a low risk of developing severe disease, according to an interim data analysis from the international clinical trial called the Study of Tecovirimat for Mpox (STOMP).

10 Dec 2024

Promising gene therapy could transform heart failure treatment

A new gene therapy can reverse the effects of heart failure and restore heart function in a large animal model.

10 Dec 2024

New triplet therapies show promise for relapsed and newly diagnosed leukemias

Three clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated significant positive results from novel triplet therapies in the treatment of relapsed or refractory and newly diagnosed leukemias.

9 Dec 2024

Scientists uncover genetic code driving tumor formation and spread

A group of scientists at VCU Massey Comprehensive Cancer Center has revealed a new genetic code that acts like a cancer ringleader, recruiting and deploying a gang of tumor cells to incite a biological turf war by invading healthy organs and overpowering the normal cells.

9 Dec 2024

New advances offer hope for patients with systemic mastocytosis

Dana-Farber Cancer Institute researchers are breaking new ground in the fight against systemic mastocytosis, a rare and heterogeneous condition that is often challenging for clinicians to accurately diagnose and treat.

9 Dec 2024

Efficacy News and Research

Insilico Medicine gets first clinical milestone payment of $10 million for XL309

Long-CoV-III-21 trial shows positive results for bovhyaluronidase azoximer in post-COVID pulmonary sequelae

Mediterranean plants show promise for cardiovascular disease treatment

PATINA trial demonstrates benefit of palbociclib in HR+ HER2+ metastatic breast cancer

Tamoxifen lowers breast cancer recurrence in good-risk DCIS patients

electronRx to launch purpleDx pulmonary disease smartphone app for remote lung function monitoring

PROSPECT-Lung trial aims to improve treatment for patients with resectable non-small cell lung cancer

Exosomes: A double-edged sword in hepatocellular carcinoma

Understanding how angiogenesis contributes to drug resistance in breast cancer

New class of antivirals shows promise against multiple viruses

Imlunestrant offers new hope for ER-positive HER2-negative breast cancer

Olaparib provides survival benefits for high-risk BRCA-positive breast cancer patients

TCR sequencing sheds light on tumor immune interactions in hepatocellular carcinoma

Prostate cancer vaccines: Progress, challenges, and future directions

Elevated PGE2 levels drive age-related skin changes and cancer risk

Interim analysis of STOMP study finds no efficacy for tecovirimat in mild to moderate Mpox cases

Promising gene therapy could transform heart failure treatment

New triplet therapies show promise for relapsed and newly diagnosed leukemias

Scientists uncover genetic code driving tumor formation and spread

New advances offer hope for patients with systemic mastocytosis

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News